Nov 19, 2021 | biomarkers, precision medicine |
because not all tumours behave the same way, biomarkers can provide information about the molecular characteristics of a tumour creating a personalized approach to treating cancer. knowing your biomarker status can determine if targeted therapies are right for you and...
Nov 17, 2021 | biomarkers, precision medicine |
when we talk about mutations, this represents a very small amount of cancer patients – in colorectal cancer for example, mutations in NTRK, MSI-h/dMMR, and BRAF are considered rare [1%, 15%, 9% respectively]. however, this actually represents respectively-...
Nov 16, 2021 | biomarkers, precision medicine |
@coloncanada through their GET PERSONAL program launched a two phase project- the first phase of the project included a The first phase of the project included a pan-tumour, pan-canadian survey that was sent to multi-disciplinary healthcare professionals aimed to...
Nov 10, 2021 | biomarkers, precision medicine |
BRAF represents one of the most frequently mutated protein kinase genes in human tumours. BRAF mutation is seen in melanoma, papillary thyroid carcinoma [including papillary thyroid carcinoma arising from ovarian teratoma], ovarian serous tumours, colorectal...
Nov 10, 2021 | biomarkers, precision medicine |
neurotrophic tyrosine receptor kinase [NTRK] oncogenic NTRK gene fusions occur in many different tumour types. while present in a majority of certain rare tumours, such as secretory carcinoma of the breast or salivary gland and infantile fibrosarcoma, they are also...
Nov 10, 2021 | biomarkers, precision medicine |
B-lymphocyte antigen CD19 or CD19 [Cluster of Differentiation 19] is a protein that is encoding by the CD19 gene and is expressed in B-cells [B-cells are a type of white blood cell]. because CD19 is expressed on all B-cells [80% of ALL, 88% of B-cell lymphomas and...
